- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03173365
The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients (BRIMOCAN)
Half-Side Controlled Analysis of the Effect of Topical Brimonidine Tartrate on the Frequency and Severity of Hand-Foot Syndrome (HFS) in Cancer Patients Receiving Antineoplastic Agents (BRIMOCAN)
Study Overview
Detailed Description
Hand-foot syndrome (HFS) is an adverse event frequently associated with the use of classical chemotherapeutic agents such as capecitabine or pegylated liposomal doxorubicin, as well as targeted cancer drugs such as sorafenib or other tyrosine-kinase inhibitors. If the toxicity progresses edematous swelling, blistering and desquamation can lead to ulcerations of the palms and soles. Additionally, patients may be affected by nail-toxicities, such as discoloration, ridging, pitting up to complete onycholysis and pain. Today, cooling of hands and feet during infusion chemotherapy as well as preventive treatment with topical formulations containing urea 10% (e.g. Excipial U10 Lipolotion®) is considered as standard of care. Yet, these strategies are limited by intricateness, patient inconvenience and low efficacy. Hence, at this point the satisfactory treatment of HFS remains an unmet medical need, as until now, no effective therapy is available to prevent or reduce HFS symptoms during the cycle of chemotherapeutic treatment.
Recently, brimonidine 3 mg/g gel (Mirvaso®) has been approved as a topical treatment of facial erythema of rosacea in adult patients. Brimonidine is an effective agonist of α2-adrenoreceptors thereby, in analogy to skin cooling, leading to peripheral vasoconstriction.
Against this background, the following hypothesis was developed:
The topical application brimonidine 3 mg/g gel (Mirvaso®) may prevent or reduce the severity of HFS in cancer patients that receive respective antineoplastic agents.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Düsseldorf, Germany, 40225
- Universitätsklinikum Düsseldorf, Klinik für Dermatologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cancer patients with solid tumors under antineoplastic therapy with capecitabine or pegylated liposomal doxorubicin.
- Patients with a life expectancy of at least 12 weeks.
- History of HFS (grades 2 to 3) in the course of the therapy
- Patients who are 18-65 years old.
- Regression of HFS to grade 1 or lower with a symmetrical grading on both hands (grade 0 or grade 1) prior to the next cycle of chemotherapy.
- not legally incapacitated
- Written informed consent from the trial subject has been obtained.
- Current treatment with capecitabine or pegylated liposomal doxorubicin
Exclusion Criteria:
- Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.
- Persons held in an institution by legal or official order.
- Participation in other interventional trials
- Drug & substance abuse
- Use of central nervous depressants (e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics)
- Patients taking alpha adrenergic agonists as medication.
- Pregnant women and nursing mothers
- Failure to use highly-effective contraceptive methods
The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly effective:
- Oral hormonal contraception ('pill')
- Vaginal hormonal contraception (NuvaRing®)
- Contraceptive plaster
- Long-acting injectable contraceptives
- Implants that release progesterone (Implanon®)
- Tubal ligation (female sterilization)
- Intrauterine devices that release hormones (hormone spiral)
Double barrier methods: This means that the following are not regarded as safe: condom plus spermicide, simple barrier methods (vaginal pessaries, condom, female condoms), copper spirals, the rhythm method, basal temperature method, and the withdrawal method (coitus interruptus).
- History of inflammatory dermatosis of hands or feet (e.g. hand eczema)
- Smoking
- Severe or unstable or uncontrolled cardiovascular disease
- Depression
- cerebral or coronary insufficiency
- Raynaud's phenomenon
- orthostatic hypotension
- thrombangiitis obliterans
- Scleroderma
- Sjögren's syndrome
- renal or hepatic impairment
- Known allergic sensitization against any of the substances applied in the study
- Patients receiving monoamine oxidase (MAO) inhibitor therapy (for example selegiline or moclobemide) and patients on tricyclic (such as imipramine) or tetracyclic (such as maprotiline, mianserin or mirtazapin) antidepressants which affect noradrenergic transmission.
- Patients receiving topical corticoids on hands or feet within 1 week prior to baseline measurement and during the entire study treatment period of up to six weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brimonidine Tartrate
The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
|
1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and time of occurence of Palms with HFS severity grade 2 or 3
Time Frame: weekly up to 6 weeks
|
Palms with HFS severity of grade 2 or 3 during 2 cycles of chemotherapy or over 6 week period by means of the National Cancer Institute Common Terminology criteria for Adverse Events (NCI-CTCAE) v4.0 grading
|
weekly up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NCI-CTCAE v4.0 grading of HFS severity
Time Frame: weekly up to 6 weeks
|
Severity of HFS after 2 cycles of chemotherapy or 6 weeks by means of the NCI-CTCAE v4.0 grading
|
weekly up to 6 weeks
|
Severity of nail toxicity
Time Frame: weekly up to 6 weeks
|
Severity of nail toxicity after 2 cycles of chemotherapy or 6 weeks by means of the NCI-CTCAE v3.0 grading
|
weekly up to 6 weeks
|
modified ppPASI grading of HFS severity
Time Frame: weekly up to 6 weeks
|
Severity of HFS after 2 cycles of chemotherapy or 6 weeks by means of a modified Palmoplantar Psoriasis Area Severity Index (ppPASI)
|
weekly up to 6 weeks
|
computer-assisted quantification of HFS severity
Time Frame: weekly up to 6 weeks
|
Severity of HFS after 2 cycles of chemotherapy or 6 weeks by means of computer-assisted quantification
|
weekly up to 6 weeks
|
HFS associated pain (by VAS scale)
Time Frame: weekly up to 6 weeks
|
Level of HFS-associated pain after 2 cycles of chemotherapy or 6 weeks by means of visual analogue scale (VAS)
|
weekly up to 6 weeks
|
Highest grade of HFS severity (NCI-CTCAE v4.0 grading)
Time Frame: weekly up to 6 weeks
|
Highest grade of HFS severity reached until 2 cycle of chemotherapy or over 6 week period by means of the NCI-CTCAE v4.0 grading
|
weekly up to 6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Peter Arne Gerber, PD Dr. med., Heinrich-Heine University, Duesseldorf
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Skin Diseases
- Disease
- Dermatitis
- Drug-Related Side Effects and Adverse Reactions
- Drug Eruptions
- Drug Hypersensitivity
- Syndrome
- Hand-Foot Syndrome
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Brimonidine Tartrate
Other Study ID Numbers
- BRIMOCAN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hand-foot Syndrome
-
Universitas SriwijayaActive, not recruitingCapecitabine | Hand and Foot Syndrome | Hand and Foot Skin ReactionIndonesia
-
China-Japan Friendship HospitalCompleted
-
Jessa HospitalHasselt UniversityRecruitingHand-foot Syndrome | Hand-foot Skin ReactionBelgium
-
Quanta MedicalNAOS Institute of Life ScienceCompletedGrade 2 Hand-foot SyndromFrance
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
China Medical University HospitalNot yet recruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHand-foot SyndromeChina
-
Instituto Brasileiro de Controle do CancerWecare Comércio de CosméticosRecruiting
-
Nan xuCompleted
-
Mahidol UniversitySiriraj HospitalRecruiting
Clinical Trials on Brimonidine Tartrate
-
AllerganCompletedRetinitis PigmentosaFrance, United States, Germany, Portugal
-
AllerganCompletedMacular DegenerationKorea, Republic of, Australia, Portugal, Germany, United States, Philippines, Italy
-
AllerganCompletedVitrectomyUnited States, Czech Republic
-
Sun Pharma Advanced Research Company LimitedCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Galderma R&DCompletedErythematous RosaceaUnited States
-
Uptown Eye SpecialistsUnknownPterygium | Subconjunctival Hemorrhage
-
AllerganCompletedRhegmatogenous Macula-off Retinal DetachmentUnited Kingdom, Korea, Republic of, Israel, India, United States, Philippines
-
Visus TherapeuticsCompleted
-
Galderma R&DCompletedErythema | RosaceaUnited Kingdom, Germany, Sweden
-
AllerganCompletedGlaucoma, Open-AngleIsrael, United States